secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2026-04-03T23:59:59+00:00
Accession:  0001178913-26-002001
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study
--------------------------------------------------------------------------------

- Gross proceeds of ~$10.0M from sale of 7,827,789 units at $1.2775/unit to funds affiliated with BVF Partners LP.
- Each unit consists of one ordinary share (or pre-funded warrant) and one warrant to purchase 1.5 ordinary shares at $1.24/share.
- Warrants become exercisable 6 months after closing (April 2, 2026) and expire in 5 years; cash exercise could bring additional ~$14.5M.
- Net proceeds intended to support initiation of phase 3 registrational study of EB613 for postmenopausal osteoporosis and for working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/0001178913-26-002001-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891326002001/zk2634965.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-002001

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer